

**IN THE UNITED STATES DISTRICT COURT  
FOR THE DISTRICT OF DELAWARE**

GENENTECH, INC. and CITY OF HOPE, )

Plaintiffs and Counterclaim Defendants, )

v. )

AMGEN INC., )

Defendant and Counterclaim Plaintiff. )

C.A. No. 18-924-CFC

---

GENENTECH, INC. and CITY OF HOPE, )

Plaintiffs and Counterclaim Defendants, )

v. )

SAMSUNG BIOEPIS CO., LTD, )

Defendant and Counterclaim Plaintiff. )

C.A. No. 18-1363-CFC

**DECLARATION OF SUSAN SHARFSTEIN, PH.D.  
IN SUPPORT OF DEFENDANTS'  
CLAIM CONSTRUCTION BRIEF**

I, Dr. Susan Sharfstein, declare as follows:

**I. Background and Qualifications**

1. I am an expert in cell culture technology. In general, cell culture refers to growing cells under controlled conditions, and it is the process by which biopharmaceutical companies produce therapeutic proteins. I have extensive experience with cell culture technology, including the formulation of cell culture media, and the use of Chinese hamster ovary (“CHO”) cells in cell culture and protein production.

2. I received my B.S. with honors in Chemical Engineering from the California Institute of Technology in 1987. I received my Ph.D. in Chemical Engineering from the University of California, Berkeley in 1993.

3. I am currently on the faculty of the State University of New York Polytechnic Institute, where I am currently Professor of Nanobioscience. Previously, I held faculty positions at other institutions including Rensselaer Polytechnic Institute, and I performed postdoctoral research at the University of California, Los Angeles, and the University of California, Berkeley.

4. Over the course of my academic career, I have conducted extensive research on a variety of cell culture-related topics. My research efforts are currently aimed at understanding the role of culture conditions and cell physiology on use of living systems for industrially relevant processes. My current projects include the

production of heparin (a critically important anticoagulant drug) in CHO cells, and studying and characterizing CHO cell clones producing recombinant monoclonal antibodies to identify factors that affect productivity.

5. My publications include over 50 articles and nine book chapters, many of which concern cell culture technology.

6. Further details regarding my background, experience, research, and publications are contained in my *curriculum vitae*, attached as Exhibit 1.

7. In the past four years, I have not testified as an expert witness at trial and have testified once by deposition in C.A. No. 17–1407-CFC.

8. I am being compensated for my time at my normal rate of \$350 per hour. My compensation does not depend on the outcome of this litigation.

## **II. Nature of Assignment and Materials Considered**

9. I have been asked by counsel for Amgen to opine regarding the construction of the claim term “glutamine-free production culture medium” in U.S. Patent Nos. 8,512,983 (the “’983 patent”) and 9,714,294 (the “’293 patent”).

10. In forming my opinions, I have relied on my knowledge, education, skills, experience, and training, in addition to the documents and materials cited in this declaration.

11. I have reviewed the ’983 patent, the ’293 patent, excerpts from their respective prosecution histories, as well as the references and materials cited in the

text of my declaration. In addition, I have reviewed the Declarations of Dr. Holly Prentice in Support of Plaintiffs' Opening Claim Construction Brief and exhibits, and the transcript of Dr. Prentice's January 17, 2019 and February 1, 2019 depositions, as well as the portions of Genentech Inc.'s Opening Claim Construction Briefs in C.A. No. 18-924-CFC and C.A. No. 17-1407-CFC regarding the '983 and '293 patents.

### **III. Person of Ordinary Skill in the Art**

12. I understand that claim terms are interpreted from the perspective of a person of ordinary skill in the art ("POSA"). I understand that a POSA is a hypothetical person who is presumed to have known the relevant art at the time of the invention.

13. For the '983 and '293 patents, I have been asked to assume that the relevant time of invention is August 11, 2009, which is the filing date of the earliest application listed on the first page of the '983 and '293 patents (provisional application No. 61/232,889).

14. I have been informed that the following factors may be considered in determining the level of ordinary skill: (A) type of problems encountered in the art; (B) prior art solutions to those problems; (C) rapidity with which innovations are made; (D) sophistication of the technology; and (E) educational level of active workers in the field.

15. In my opinion, a POSA would have had a Ph.D. in chemical engineering, molecular biology, or a closely related field, and at least 2-3 years of experience related to cell culture media and protein and/or antibody production in cell culture.

#### **IV. Legal Standards for Claim Construction**

16. The purpose of this section is to summarize the instructions I have been provided by counsel regarding legal standards for claim construction to apply in connection with preparing my opinion.

17. I am informed that patent claims define the scope of the patented invention, and they must be definite in that they must particularly point out and distinctly claim the invention.

18. I am informed that words in a claim are generally given their ordinary and customary meaning to a POSA, in view of the context of the claim language in which the term appears, other claims, the specification and figures of the patent, and the prosecution history. I understand that these sources are collectively called the “intrinsic evidence,” and that claim terms must be interpreted in light of the intrinsic evidence because a POSA would read the term in the context of the intrinsic evidence.

19. I am informed by counsel that the claim language, specification, and figures are deemed highly relevant to understanding the meaning of a claim term.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.